By Fineline Cube Recursion (NASDAQ: RXRX) and Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY), together with its subsidiary Genentech, announced a milestone in their up‑to‑USD 12 billion artificial intelligence (AI) drug discovery collaboration. The companies plan to co‑develop a neuroscience small molecule early discovery program based on the first validated target discovered through an AI map they jointly created to identify new targets in a long‑challenging therapeutic area.
Milestone Overview
| Item | Detail |
|---|---|
| Partners | Recursion (NASDAQ: RXRX) + Roche Holding (SWX: ROP; OTCMKTS: RHHBY) / Genentech |
| Collaboration Value | Up to USD 12 billion |
| Milestone | First validated target discovered via jointly created AI map |
| Trigger | Genentech exercised the collaboration’s first validated target option |
| Payment Triggered | USD 3 million milestone payment to Recursion |
| Therapeutic Focus | Neuroscience small molecule early discovery program |
Target Validation & Payment Details
- Validation Package: Genentech exercised the collaboration’s first validated target option after accepting a validation package for the target from Recursion.
- Milestone Payment: The acceptance triggered a USD 3 million milestone payment from the biopharma giants to Recursion.
- Cumulative Cash: Since the AI‑based drug developer joined forces with Roche and Genentech to launch the partnership in 2021, total cash paid out by the biopharma giants to Recursion has reached USD 216 million.
- Timeline: Recursion said it took the companies 15 months to go from initiation of target validation to a completed validation package.
- Undisclosed Details: The companies are not disclosing what the validated target is, or what neurological disorders it has the potential to treat.
Commercial Terms Per Program
| Term | Detail |
|---|---|
| Milestone Payments | Up to USD 300 million per program (development, commercialization, and net sales milestones) |
| Royalties | Tiered royalties up to high single digits per small molecule program |
| Committed Programs | 40 programs across the platform |
| Therapeutic Scope | “Key areas” of neuroscience; an undisclosed gastrointestinal‑oncology indication |
Roche and Genentech have committed to using Recursion’s platform to advance therapies in 40 programs that include “key areas” of neuroscience and an undisclosed gastrointestinal‑oncology indication.
Market Impact & Outlook
- AI Validation: The first exercised target option provides tangible evidence that Recursion’s AI mapping approach can generate targets accepted by one of the world’s largest pharmaceutical R&D organizations — a closely watched proof point for AI‑driven drug discovery.
- Revenue Stream: With USD 216 million already paid since 2021 and up to USD 300 million in additional milestones available per program, the alliance represents a durable potential revenue stream for Recursion as it balances platform investment against cash generation.
- Neuroscience Bet: The focus on neuroscience — historically one of the highest‑failure‑rate areas in drug development — underscores the thesis that AI‑derived target discovery may unlock biology that conventional approaches have missed.
- Pipeline Optionality: The commitment to 40 programs spanning neuroscience and gastrointestinal oncology gives the partnership multiple shots on goal, even with the first validated target’s identity and indications undisclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the Recursion–Roche/Genentech collaboration, including co‑development plans, milestone payments, and program commitments. Actual results may differ due to risks including target validation outcomes, clinical results, and regulatory decisions.-Fineline Info & Tech